Nvidia's secret lab in Israel will develop drugs using AI

Nvidia's Chief Technology Officer, Michael Kagan, has established a new research group in Israel called Applied AI Architecture, which will operate at the company's development center in Tel Aviv and focus on accelerating scientific and medical discoveries through artificial intelligence. The group operates under Nvidia's global CTO office, headed by Kagan, who reports directly to Jensen Huang. The group is led by Dr. Nati Daniel, who holds a PhD in artificial intelligence from the Technion and previously held senior positions at Intel, GE, and Huawei. The group collaborates with Sheba Medical Center and Mount Sinai Hospital in New York on developing a genomic AI model called gFM, designed to help research 98% of the human genome that has yet to be deeply explored. Additionally, the group is involved in Nvidia's global collaboration with pharmaceutical company Eli Lilly, in which the two companies will invest about one billion dollars over five years in harnessing AI for drug discovery and development. The group also participates in the GENMAT project, an international research initiative that received a grant of about 6 million euros from the European Union's Horizon program, to develop AI tools for accelerating the discovery of new materials. Nvidia plans to recruit dozens more researchers in the coming year.